Emmanuel Hanon, Vicebio CEO (PRNewswire/Viome)
July 21, 2022 07:07 AM EDTUpdated July 22, 10:00 AM
Financing
Startups

One year af­ter leav­ing GSK, Em­manuel Hanon jumps to Medicxi-backed vac­cine start­up with an eye on RSV

Tyler Patchen

News Reporter

Af­ter 20 years of ser­vice at GSK — lead­ing glob­al vac­cines R&D for the last sev­en — Em­manuel Hanon left last year for a well­ness com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times